Treatment of chronic hepatitis C (cHC) with peginterferon Alfa-2a (40KD) (PEG) and ribavirin (RBV) in patients older than 60 years

被引：0
|
作者：
Meyer, Ulrike
Zehnter, Elmar
Mauss, Stefan
Boeker, Klaus
Lutz, Thomas
Racky, Stefan
Schmidt, Wolfgang
Ullrich, Rainer
Sbrijer, Innessa
Heyne, Renate
Schober, Andreas
John, Christine
Hey, Karl-Heinz
Bokemeyer, Bernd
Kallinowski, Birgit
Moeller, Bernd
Pape, Stefan
Alshuth, Ulrich
Hueppe, Dietrich
机构：
来源：
GASTROENTEROLOGY | 2007年 / 132卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A790 / A791
页数：2
相关论文
共 50 条
  • [41] The cost-effectiveness of peginterferon alfa-2a (40kd) (PEGASYS) plus ribavirin (COPEGUS) vs. interferon alfa-2b plus ribavirin for chronic hepatitis C (CHC)
    Sullivan, SD
    Green, J
    Patel, KK
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    VALUE IN HEALTH, 2003, 6 (03) : 262 - 263
  • [42] Population pharmacokinetics of single- or multiple-dose ribavirin (Copegus®) administered with or without peginterferon alfa-2a (40KD) (Pegasys®) in chronic hepatitis c (CHC) patients
    Wade, Janet
    Snoeck, Eric
    Lamb, Matthew
    Duff, Frank
    Wang, Karen
    Grippo, Joseph
    Jorga, Karin
    GASTROENTEROLOGY, 2006, 130 (04) : A838 - A838
  • [43] Cost-effectiveness of first-line peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) in patients with mild chronic hepatitis C (cHC) in the US
    El-Serag, Hashem B.
    Patel, Kavita K.
    Wintfeld, Neil
    Green, Jesse
    Sullivan, Sean D.
    GASTROENTEROLOGY, 2006, 130 (04) : A837 - A837
  • [44] Sustained virological response (SVR) to peginterferon alfa-2a (40KD) (pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC
    Fargion, S
    Borzio, M
    Maraschi, A
    Cargnel, A
    JOURNAL OF HEPATOLOGY, 2004, 40 : 140 - 140
  • [45] Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a (40KD) (PEGASYS™) alone versus Peginterferon alfa-2a (40KD) plus ribavirin(COPEGUS™) in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a (40KD) plus ribavirin:: An open, multicenter, randomized trial.
    Bronowicki, JP
    Ouzan, D
    Tzanck, A
    Asselah, T
    Desmorat, H
    Zarski, JP
    Foucher, J
    Bourliere, M
    Renou, C
    Tran, A
    Melin, P
    Hezode, C
    Chevallier, M
    Bouvier, M
    Lonjon-Domanec, I
    Pawlotsky, JM
    HEPATOLOGY, 2003, 38 (04) : 244A - 245A
  • [46] Peginterferon alfa-2a (40KD): A potent long-acting form of interferon alfa-2a for the treatment of hepatitis C
    Modi, MW
    Lamb, MW
    Shiomi, M
    POLYMER DRUGS IN THE CLINICAL STAGE: ADVANTAGES AND PROSPECTS, 2003, 519 : 59 - 67
  • [47] CONFIRMATION OF HIGH SVR RATES AFTER SHORTENING DURATION OF TREATMENT WITH PEGINTERFERON ALFA-2A (PEG) AND RIBAVIRIN (RBV) IN CHRONIC HEPATITIS C (CHC) PATIENTS WITH RVR IN REAL LIFE
    Baloch, Baby Kanwal
    Chen, Liqiong
    Irving, William
    Ilyas, Mohammad
    Thomson, Brian J.
    HEPATOLOGY, 2011, 54 : 806A - 807A
  • [48] Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin
    Reau, Nancy
    Hadziyannis, Stephanos J.
    Messinger, Diethelm
    Fried, Michael W.
    Jensen, Donald M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (08): : 1981 - 1988
  • [49] Cost-effectiveness of peginterferon alfa-2a (40KD) for the treatment of chronic Hepatitis B in Italy
    Eandi, M.
    Iannazzo, S.
    Pradelli, L.
    Patel, K.
    Giuliani, G.
    VALUE IN HEALTH, 2006, 9 (06) : A301 - A302
  • [50] Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels
    Pockros, PJ
    Diago, M
    Gane, E
    Reddy, KR
    Prati, D
    Shiffman, ML
    Farci, P
    O'Brien, C
    Lardelli, P
    Lamour, F
    Zeuzem, S
    JOURNAL OF HEPATOLOGY, 2004, 40 : 148 - 148
12345